Palvella Therapeutics, Inc. (PVLA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 11.95M USD | Liabilities, Current |
| Cash and equivalents | 187.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.95M | $187.80M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $9.12M | $206.39M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $11.34M | $57.98M | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | $10.31M | $63.57M | (m) | $0.00 | (m) | (m) |
| 2025-06-30 | (m) | $9.62M | $70.43M | (m) | $0.00 | (m) | (m) |
| 2025-03-31 | (m) | $8.98M | $75.63M | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | $12.04M | $83.60M | (m) | $358.00K | (m) | (m) |
| 2024-09-30 | (m) | $4.25M | $19.36M | (m) | $373.00K | (m) | (m) |
| 2024-06-30 | (m) | $6.35M | $19.73M | (m) | $1.49M | (m) | (m) |
| 2024-03-31 | (m) | $7.53M | $19.08M | (m) | $1.84M | (m) | (m) |
| 2023-12-31 | (m) | $11.92M | $17.40M | (m) | $572.00K | (m) | (m) |
| 2023-09-30 | (m) | $28.87M | $32.89M | (m) | $1.04M | (m) | (m) |
| 2023-06-30 | (m) | $34.37M | $44.94M | (m) | $952.00K | (m) | (m) |
| 2023-03-31 | (m) | $42.88M | $39.74M | (m) | $1.05M | (m) | (m) |
| 2022-12-31 | (m) | $36.58M | $38.63M | (m) | $5.81M | (m) | (m) |
| 2022-09-30 | (m) | $33.52M | $48.42M | (m) | $829.00K | (m) | (m) |
| 2022-06-30 | (m) | $35.55M | $54.26M | (m) | $1.26M | (m) | (m) |
| 2022-03-31 | (m) | $39.48M | $83.74M | (m) | $1.64M | (m) | (m) |
| 2021-12-31 | (m) | $50.56M | $117.76M | (m) | $3.31M | (m) | (m) |
| 2021-09-30 | (m) | $49.70M | $125.05M | (m) | $6.65M | (m) | (m) |
| 2021-06-30 | (m) | $43.93M | $119.10M | (m) | $2.80M | (m) | (m) |
| 2021-03-31 | (m) | $30.27M | $66.83M | (m) | $15.81M | (m) | (m) |
| 2020-12-31 | (m) | $22.14M | $70.44M | (m) | $1.71M | (m) | (m) |
| 2020-09-30 | (m) | $19.69M | $66.89M | (m) | $2.94M | (m) | (m) |
| 2020-06-30 | (m) | $18.26M | $44.30M | (m) | $10.71M | (m) | (m) |
| 2020-03-31 | (m) | $20.48M | $47.43M | (m) | $7.27M | (m) | (m) |
| 2019-12-31 | (m) | $27.00M | $62.26M | (m) | $6.79M | (m) | (m) |
| 2019-09-30 | (m) | $39.85M | $46.07M | (m) | $6.95M | (m) | (m) |
| 2019-06-30 | (m) | $40.93M | $54.90M | (m) | $7.17M | (m) | (m) |
| 2019-03-31 | (m) | $41.13M | $52.09M | (m) | $7.13M | (m) | (m) |
| 2018-12-31 | (m) | $48.08M | $74.87M | (m) | $2.70M | (m) | (m) |
| 2018-09-30 | (m) | $40.59M | $89.48M | (m) | $5.34M | (m) | (m) |
| 2018-06-30 | (m) | $52.33M | $50.58M | (m) | $2.56M | (m) | (m) |
| 2018-03-31 | (m) | $54.76M | $109.52M | (m) | $3.31M | (m) | (m) |
| 2017-12-31 | (m) | $45.77M | $37.88M | (m) | $15.55M | (m) | (m) |
| 2017-09-30 | (m) | $39.04M | $89.92M | (m) | $2.54M | (m) | (m) |
| 2017-06-30 | (m) | $35.80M | $50.33M | (m) | $48.47M | (m) | (m) |
| 2017-03-31 | (m) | $11.44M | $55.24M | (m) | $39.01K | (m) | (m) |
| 2016-12-31 | (m) | $8.38M | $29.36M | (m) | $57.58K | (m) | (m) |
| 2016-09-30 | (m) | $9.95M | $36.56M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $6.42M | $40.37M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $6.50M | $31.19M | (m) | $70.26K | (m) | (m) |
| 2015-12-31 | (m) | $2.80M | $29.35M | (m) | $0.00 | (m) | (m) |
| 2015-09-30 | (m) | $2.24M | $32.25M | (m) | $17.36K | (m) | (m) |
| 2015-06-30 | (m) | $3.02M | $10.03M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $2.25M | $13.17M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $3.54M | $18.47M | (m) | $0.00 | (m) | (m) |
| 2014-09-30 | (m) | (m) | $220.00 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $11.14K | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $196.00 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $90.00 | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $688.00 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $5.20K | (m) | (m) | (m) | (m) |
| 2013-05-23 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $6.33M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |